Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

StoneX Group clearly didn’t skip leg day—it just bulked up its Pfizer holdings by a massive 43.5% in Q4, scooping up over ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include younger adults, and announced a collaboration with Flagship Pioneering for ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Analysts believe Gilead could climb to a new 52-week high near $130, representing a potential 16.1% upside from current levels. For investors looking for strength and stability in today’s uncertain ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Pfizer’s stock has underperformed lately, falling 4.6% while still doing marginally better than its peers. Analysts have made ...

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 20.19%, which has investors questioning if this is right time to ...